GlassScriptPhysician profile
Inderjit S Kainth
NPI 1194763029
$6,187.99
in general payments reported to CMS, 2019-2025
35 companies · $721 in 2025
The $721 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $983 · 2021: $1,587 · 2022: $651 · 2023: $421 · 2024: $946 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,672.80 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $606.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $585.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $377.12 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $318.54 | 2019-2024 | |
| Pfizer INC. | $298.58 | 2019-2023 | |
| Abbott Laboratories | $287.53 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.02 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $220.70 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $211.78 | 2019-2022 | |
| Medtronic, INC. | $187.50 | 2021 | |
| Merck Sharp & Dohme LLC | $169.38 | 2019-2021 | |
| Horizon Therapeutics Plc | $135.49 | 2019 | |
| Biotronik INC. | $117.64 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $80.63 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $80.10 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $58.13 | 2021-2024 | Zoryve |
| Amgen INC. | $58.09 | 2022-2023 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.32 | 2020-2025 | Caplyta |
| Saluda Medical Americas, INC. | $51.18 | 2024 | Evoke |
| Abbvie INC. | $49.00 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $47.68 | 2024-2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $39.92 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $39.18 | 2020-2021 | |
| Allergan, INC. | $37.78 | 2020 | |
| Boston Scientific Corporation | $27.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.66 | 2022 | |
| Renalytix Ai, INC. | $19.65 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Dexcom, INC. | $18.13 | 2025 | Dexcom G6 Transmitter |
| Tonix Medicines, INC. | $16.65 | 2025 | Tonmya |
| Phadia US INC. | $16.05 | 2024 | Immunocap |
| Avanir Pharmaceuticals, INC. | $13.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.63 | 2019 | |
| Daiichi Sankyo INC. | $12.66 | 2020 | |
| Genentech USA, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inderjit Kainth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.